Precision BioSciences to Present at Upcoming Virtual Investor Conferences
02 March 2021 - 11:00PM
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
biotechnology company developing allogeneic CAR T and in vivo gene
correction therapies with its ARCUS® genome editing platform, today
announced management will participate in the following upcoming
virtual investor conferences:
H.C. Wainwright Global Life Sciences
Conference Date: Tuesday, March 9, 2021 The fireside chat
will be available on demand beginning at 7:00 AM ET with an
archived replay available for 90 days.
Barclays Global Healthcare
Conference Date: Tuesday, March 9, 2021 Presentation:
10:55 AM ET An archived replay of this corporate presentation will
be available for one year.
Webcasts will be accessible on the Company’s
website, www.precisionbiosciences.com, in the Investors & Media
section under Events and Presentations.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
specific and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the Company’s pipeline consists of multiple “off-the-shelf”
CAR T immunotherapy clinical candidates and several in vivo gene
correction therapy candidates to cure genetic and infectious
diseases where no adequate treatments exist. For more information
about Precision BioSciences, please visit
www.precisionbiosciences.com.
Investor Contact: Alex Kelly
Interim Chief Financial Officer
Alex.Kelly@precisionbiosciences.com
Media Contact: Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Apr 2023 to Apr 2024